These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36289451)

  • 1. A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials.
    Cabarrou B; Leconte E; Sfumato P; Boher JM; Filleron T
    BMC Med Res Methodol; 2022 Oct; 22(1):278. PubMed ID: 36289451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.
    Cabarrou B; Sfumato P; Mourey L; Leconte E; Balardy L; Martinez A; Delord JP; Boher JM; Brain E; Filleron T
    Eur J Cancer; 2018 Nov; 103():120-126. PubMed ID: 30223225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package.
    Cabarrou B; Sfumato P; Leconte E; Boher JM; Filleron T
    Comput Biol Med; 2018 Sep; 100():239-246. PubMed ID: 30055524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
    Roig MB; Melis GG; Posch M; Koenig F
    Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints.
    Sinha AK; Moye L; Piller LB; Yamal JM; Barcenas CH; Lin J; Davis BR
    Stat Med; 2019 Sep; 38(21):3985-3996. PubMed ID: 31184783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
    Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
    Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An optimal stratified Simon two-stage design.
    Parashar D; Bowden J; Starr C; Wernisch L; Mander A
    Pharm Stat; 2016 Jul; 15(4):333-40. PubMed ID: 26932771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
    Neven A; Mauer M; Hasan B; Sylvester R; Collette L
    J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.
    Cabarrou B; Mourey L; Dalenc F; Balardy L; Kanoun D; Roché H; Boher JM; Rougé-Bugat ME; Filleron T
    Breast Cancer Res Treat; 2017 Aug; 164(3):505-513. PubMed ID: 28488143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal predictive probability designs for randomized biomarker-guided oncology trials.
    Zabor EC; Kaizer AM; Pennell NA; Hobbs BP
    Front Oncol; 2022; 12():955056. PubMed ID: 36561534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
    Yoo W; Kim S; Garcia M; Mehta S; Sanai N
    BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
    Xu T; Shi H; Lin R
    Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II selection design with order constrained strata.
    Chen Y; Yu M
    Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The extension of 2-in-1 adaptive phase 2/3 designs and its application in oncology clinical trials.
    Fan L; Zhao J; Li W
    Contemp Clin Trials; 2020 Nov; 98():106148. PubMed ID: 32949732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.